Should the Availability of High-Dose Opioids Be Reduced?

In this video from PainWeek 2017, Hal Blatman, MD, medical director of Blatman Health and Wellness Center, discusses whether the FDA should reduce the availability of high-dose opioids in response to the growing opioid abuse epidemic.

In this video from PainWeek 2017, Hal Blatman, MD, medical director of Blatman Health and Wellness Center, discusses whether the FDA should reduce the availability of high-dose opioids in response to the growing opioid abuse epidemic.

Related Content:

ConferencePain ManagementRetail
Celebrating Pharmacists During American Pharmacists Month 2022
Pharmacy Times and Parata Systems Announce the 2022 Next-Generation Pharmacist Award Winners
Understanding of Mutations Influences Treatment for Patients With Waldenstrom Macroglobulinemia